1. Intrepid Health Solutions Ematuzumab Launch November 15, 2013 TEAM 1 David Waintraub Jason Bloom Manasa Parakala Michael Kwatkoski

2. Executive Summary WHO? WHAT? WHERE? WHEN? WHY? HER2/neu Breast Cancer Patients Ematuzumab-Disruptive Monoclonal Antibody Launch in the United States FDA Approval by 2015 Risk Sharing Pricing Model High Complete Response Rate No Cardiac Risk High Overall Survival 2

3. What is HER2/neu? Biomarker: promotes cancer cell growth Causes aggressive cancer 38,400 diagnosed each year Standard of Care: Genetech’s Herceptin New Paradigm: Perjeta enhances Herceptin’s effectiveness 3

4. Breast Cancer Continuum Before SurgeryAfter SurgeryBefore/After Surgery 1 st Line2 nd 3 rd 4 th HER2/neu : 38,400 patients/year 4 Neo- Adjuvant AdjuvantMetastatic Stage IIIIII

5. Perjeta Landscape Before SurgeryAfter SurgeryBefore/After Surgery Stage IIIIII 1 st Line2 nd 3 rd 4 th EEEEEEEEEEEE PPPPPPPPPPPP 5 Neo- Adjuvant AdjuvantMetastatic

6. Metastatic 1 st Line: Ema vs. Perjeta Comparative Effectiveness Research ResultsEma ProjectedPerjeta ActualPlacebo Complete Response 8.4%5.5%4.2% Overall Survival>50 months~50 months37.6 months SafetyNo Cardiac RiskCardiac Risk PFS5.5 months6.1 months - Administration60 min60 min, 30-60min - 6

7. Breast Cancer Continuum Before SurgeryAfter SurgeryBefore/After Surgery Stage IIIIII 1 st Line2 nd 3 rd 4 th HER2/neu : 38,400 patients/year 7 Neo- Adjuvant AdjuvantMetastatic

8. Neoadjuvant: Ema vs. Perjeta Comparative Effectiveness Research ResultsEma ProjectedPerjeta ActualPlacebo pCR>39.3% 39.3%21.5% Secondary Endpoint No Cardiac RiskCardiac Risk 8

9. Breast Cancer Continuum Before SurgeryAfter SurgeryBefore/After Surgery Stage IIIIII HER2/neu : 38,400 patients/year 9 Neo- Adjuvant AdjuvantMetastatic 1 st Line2 nd 3 rd 4 th

10. Pricing Argument Ematuzumab: $6500/month Perjeta: $5900/month Comparative Effectiveness Research Risk sharing model Lower overall health care costs 10

11. Comparative Effectiveness Research Stronger Complete Response Stronger Overall Survival No Cardiac Risk 11

12. Risk Sharing Model Ema ProjectedPerjeta Actual Price per patient $6500/month$5900/month Rebate 20% based on ORR $1300$0 Adjusted price after rebate $5200$5900 Savings$700$0 12

13. Lower Overall Healthcare Costs Value Based Purchasing Shifting story from price of drug to overall cost of care High Complete Response No Cardiac Risk Accountable Care Organizations Pay for total continuum of patient Look at drug’s efficacy Overall cost 13

14. Better Drug, Better Plan Have better results for less costs Head to head studies Risk sharing model Uniform message to medical community Payors, physicians, and patients 14

15. Pre-Launch Plan Timeline of Phase III Data San Antonio Breast Cancer Symposium: December 2013 Metastatic 1 st Line Phase III Data American Society of Clinical Oncology: June 2014 Neo-Adjuvant Phase III Data 15

16. 16 STRENGTHS Higher Complete Response Higher Overall Survival No Cardiac Risk Innovative Pricing Model OPPORTUNITIES Adjuvant 2 nd line metastatic Potential to expand in oncology THREATS Phase III results weaker than projected New product launches in the breast cancer space WEAKNESSES 2 nd to Market Genentech franchise 1 st time in oncology Progression Free Survival Longer drug administration Ema SWOT Analysis

17. Questions? 17